• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     National Institute for Health and Care Excellence (NICE) UroShield for preventing catheter-associated urinary tract infections. NICE medical technologies guidance 69
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022     Health Technology Wales (HTW) Continuous topical oxygen therapy to treat people with chronic non-healing and complex diabetic foot ulcers
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal). NICE technology appraisal guidance 839
2022     National Institute for Health and Care Excellence (NICE) Prontosan for treating acute and chronic wounds. NICE medical technologies guidance 67
2022     NIHR Health Technology Assessment programme Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2022     Health Sciences Institute in Aragon (IACS) Efficacy, safety and efficiency of sentinel lymph node magnetic localisation techniques in breast cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duvelisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2022     The Regional Health Technology Assessment Centre (HTA-centrum) Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies
2022     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal). NICE technology appraisal guidance 840
2022     National Institute for Health and Care Excellence (NICE) 3C Patch for treating diabetic foot ulcers. NICE medical technologies guidance 66
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2022     WorkSafeBC Dry needling for lateral elbow pain
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duvelisib (follicular lymphoma) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 841
2022     National Institute for Health and Care Excellence (NICE) Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care. NICE medical technologies guidance 65
2022     Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2022     WorkSafeBC Efficacy and/or effectiveness of treatments for lateral epicondylitis - barbotage and ultrasonic tenotomy
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal). NICE technology appraisal guidance 842
2022     WorkSafeBC Fat grafting for nerve padding
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal). NICE technology appraisal guidance 843
2022     WorkSafeBC Intravenous ketamine for PTSD and treatment-resistant depression
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162]
2022     National Institute for Health and Care Excellence (NICE) Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal). NICE technology appraisal guidance 844
2022     National Institute for Health and Care Excellence (NICE) Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment). NICE diagnostics guidance 47
2022     Medical Services Advisory Committee (MSAC) Genetic testing for childhood hearing impairment
2022     NIHR Health Technology Assessment programme The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) The role of early CT Coronary Angiography in the evaluation, intervention and outcome of patients presenting to the Emergency Department with suspected or confirmed Acute Coronary Syndrome
2022     Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2022     WorkSafeBC Sweat lodge usage as treatment for depression or other psychological disorders
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Addendum to Commission A21-164]
2022     National Institute for Health and Care Excellence (NICE) Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal). NICE technology appraisal guidance 845
2022     Medical Services Advisory Committee (MSAC) Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule-subsidised aducanumab in patients with early stage Alzheimer disease
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glucarpidase (toxic MTX plasma concentrations) - Assessment according to §35a SGB V (1), Sentence 11]
2022     National Institute for Health and Care Excellence (NICE) Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal). NICE technology appraisal guidance 846
2022     Norwegian Institute of Public Health (NIPH) Surgical procedures for treatment of obesity: health technology assessment
2022     Health Technology Wales (HTW) Closed loop systems for the management of type 1 diabetes mellitus in adults and children
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voxelotor (sickle cell disease) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 847
2022     NIHR Health Technology Assessment programme Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC)
2022     Penn Medicine Center for Evidence-based Practice (CEP) Organizational strategies to improve or promote healthcare worker wellness
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (small bowel cancer) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 848
2022     NIHR Health Technology Assessment programme Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2022     Norwegian Institute of Public Health (NIPH) First trimester-screening for the development of preeclampsia with the use of an algorithm: a health technology assessment
2022     Health Technology Wales (HTW) Photobiomodulation for the prevention and treatment of oral mucositis and radiation dermatitis associated with cancer treatment
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (bile cancer) - Benefit assessment according to § 35a SGB V]
2022     National Institute for Health and Care Excellence (NICE) Cabozantinib for previously treated advanced hepatocellular carcinoma. NICE technology appraisal guidance 849
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 2 - overview of liver transplantation in Québec]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53]
2022     National Institute for Health and Care Excellence (NICE) Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NICE technology appraisal guidance 850
2022     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease
2022     Health Technology Wales (HTW) Wearable cardioverter-defibrillators for people at risk of cardiac death
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal carcinoma, combination with chemotherapy) - Addendum to Commission A22-54]
2022     Agency for Healthcare Research and Quality (AHRQ) Management of infantile epilepsies
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. NICE technology appraisal guidance 851
2022     NIHR Health Technology Assessment programme VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot. The VIOLET Study
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis, combination with rituximab or cyclophospha-mide)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Number of tonsillitis episodes: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     National Institute for Health and Care Excellence (NICE) Trifluridinetipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments. NICE technology appraisal guidance 852
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ripretinib (gastrointestinal stromal tumours (GIST), ≥ 3 prior therapies)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Avatrombopag for treating primary chronic immune thrombocytopenia. NICE technology appraisal guidance 853
2022     Agency for Care Effectiveness (ACE) Guardant360 CDx for patients with locally advanced or metastatic non-small cell lung cancer
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of convalescent plasma donor therapy in the treatment of COVID-19]
2022     National Institute for Health and Care Excellence (NICE) Esketamine nasal spray for treatment-resistant depression. NICE technology appraisal guidance 854
2022     Agency for Care Effectiveness (ACE) The Signatera test for patients previously diagnosed with cancer
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: somatic variant classification and stratification strategies]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: next generation sequencing hereditary cancer gene panels]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Healthcare Research and Quality (AHRQ) Maternal and child outcomes associated with the Special Supplemental Nutrition Program for women, infants, and children (WIC)
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Solriamfetol (obstructive sleep apnoea) - Benefit assessment according to §35a Social Code Book V]
2022     Health Sciences Institute in Aragon (IACS) [Non-perforating deep sclerectomy (NPDS) in open angle primary glaucoma (POAG)]
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Smila Care Service
2022     NIHR Health Technology Assessment programme Liaison Psychiatry: Measurement And Evaluation of Service Types, Referral patterns and Outcomes LP-MAESTRO
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; adjuvant treatment) - Addendum to Commission A22-51]
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Monidor solution for the implementation of intravenous fluid therapy
2022     NIHR Health Technology Assessment programme Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial
2022     NIHR Health Technology Assessment programme Comparison of ALitretinoin with PUVA as the first line treatment in patients with severe chronic HAnd eczema (ALPHA trial)
2022     Agency for Care Effectiveness (ACE) Nivolumab for treating gastroesophageal cancers
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35]
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Hygga Flow Enterprise Resource Planning System
2022     NIHR Health Technology Assessment programme Early detection of neovascular age-related macular degeneration
2022     Agency for Care Effectiveness (ACE) Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) The Orla INR Remote Monitoring
2022     Agency for Healthcare Research and Quality (AHRQ) Models of care that include primary care for adult survivors of childhood cancer: a realist review
2022     NIHR Health Technology Assessment programme Intravenous immunoglobulin in the management of encephalitis in children
2022     Agency for Care Effectiveness (ACE) SGLT2 inhibitors for treating heart failure with reduced ejection fraction and chronic kidney disease